Abstract:
:A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52±0.36 vs. 4.19±0.58, p=0.001; virological response [VR], 4.53±0.35 vs. 4.22±0.57, p=0.005; combined response [CR], 4.50±0.36 vs. 4.22±0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels ≥30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.
journal_name
Theranosticsjournal_title
Theranosticsauthors
Hou FQ,Song LW,Yuan Q,Fang LL,Ge SX,Zhang J,Sheng JF,Xie DY,Shang J,Wu SH,Sun YT,Wei SF,Wang MR,Wan MB,Jia JD,Luo GH,Tang H,Li SC,Niu JQ,Zhou WD,Sun L,Xia NS,Wang GQdoi
10.7150/thno.10636subject
Has Abstractpub_date
2015-01-01 00:00:00pages
218-26issue
3issn
1838-7640pii
thnov05p0218journal_volume
5pub_type
杂志文章,多中心研究,随机对照试验相关文献
Theranostics文献大全abstract::Comprehensive analysis of the expression level and location of tumor-associated membrane proteins (TMPs) is of vital importance for the profiling of tumor cells. Currently, two kinds of independent techniques, i.e. ex situ detection and in situ imaging, are usually required for the quantification and localization of T...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.22794
更新日期:2018-01-01 00:00:00
abstract::Phenylboronic acid (PBA)-mediated tumor targeting nanovector is an attractive strategy for enhancing siRNA delivery and treatment of metastatic cancers. However, its nonspecific binding with various biological membranes containing cis-diol moieties restricts its potential application by systematic administration. Here...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.16855
更新日期:2017-01-01 00:00:00
abstract::Reactive oxygen species (ROS) play a crucial role in cancer formation and development, especially cancer metastasis. However, lack of a precise tool, which could accurately distinguish specific types of ROS, restricts an in-depth study of ROS in cancer development and progression. Herein, we designed smart and versati...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.38422
更新日期:2020-02-10 00:00:00
abstract::Aim: Immune responsive 12/15 lipoxygenase (12/15LOX)-orchestrate biosynthesis of essential inflammation-resolution mediators during acute inflammatory response in post-myocardial infarction (MI). Lack of 12/15LOX dampens proinflammatory mediator 12-(S)-hydroxyeicosatetraenoic acid (12-(S)-HETE), improves post-MI survi...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.51183
更新日期:2021-01-01 00:00:00
abstract::Inhibitor of apoptosis proteins (IAP) are cell death regulators that bind caspases and interfere with apoptotic signalling via death receptors or intrinsic cell death pathways. BIRC4/XIAP is the most potent anti-apoptotic IAP-member and it physically interacts with caspases via its BIR2 and its BIR3 domain. These doma...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.33758
更新日期:2019-07-09 00:00:00
abstract::Background: Programmed cell death protein 1 (PD1) inhibitors have revolutionized cancer therapy, yet many patients fail to respond. Thus, the identification of accurate predictive biomarkers of therapy response will improve the clinical benefit of anti-PD1 therapy. Method: We assessed the baseline serological autoanti...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.45816
更新日期:2020-05-16 00:00:00
abstract::Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short-lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this enables patient se...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.34941
更新日期:2019-10-15 00:00:00
abstract::Angiogenesis enhances cancer metastasis and progression, however, the roles of transcription regulation in angiogenesis are not fully defined. ZNF322A is an oncogenic zinc-finger transcription factor. Here, we demonstrate a new mechanism of Kras mutation-driven ZNF322A transcriptional activation and elucidate the inte...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.47491
更新日期:2020-08-08 00:00:00
abstract::Background: Biofilm infection caused by multidrug-resistant bacteria is difficult to eradicate by conventional therapies. Photodynamic therapy (PDT) is an effective antibacterial method for fighting against biofilm infection. However, the blocked photosensitizers outside of biofilm greatly limit the efficacy of PDT. M...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.42922
更新日期:2020-03-26 00:00:00
abstract::Topical administration permits targeted, sustained delivery of therapeutics to human skin. Delivery to the skin, however, is typically limited to lipophilic molecules with molecular weight of < 500 Da, capable of crossing the stratum corneum. Nevertheless, there are indications protein delivery may be possible in barr...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.21668
更新日期:2018-01-01 00:00:00
abstract::Rationale: Colitis-associated colorectal cancer (CAC) usually exhibits an accelerated disease progression, an increased resistance to therapeutic drugs and a higher mortality rate than sporadic colorectal cancer (CRC). PIAS3 is a member of the protein inhibitor of activated STAT (PIAS) family; however, little is known...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.23046
更新日期:2018-04-30 00:00:00
abstract::Rationale: Subjects unable to sustain β-cell compensation develop type 2 diabetes. Early growth response-1 protein (EGR-1), implicated in the regulation of cell differentiation, proliferation, and apoptosis, is induced by diverse metabolic challenges, such as glucose or other nutrients. Therefore, we hypothesized that...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.40664
更新日期:2020-03-04 00:00:00
abstract::Non-invasive PET imaging of CXCR4 expression in cancer and inflammation as well as CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical research by the development of the theranostic agents [68Ga]PentixaFor (cyclo(D-Tyr1-D-[NMe]Orn2(AMBS-[68Ga]DOTA)-Arg3-Nal4-Gly5) = [68Ga]DOTA-AMBS-CPC...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.45537
更新日期:2020-07-09 00:00:00
abstract::Dendritic cells (DC) and tumor cell fusion vaccine (DC/tumor cell fusion vaccine) is considered an effective approach in cancer biotherapy. However, its therapeutic effects in early clinical trials have been suboptimal partially due to the immunosuppressive tumor environment. In this study, we used nanoparticles of fo...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.16236
更新日期:2017-05-02 00:00:00
abstract::Rationale: Mesenchymal cell-derived osteosarcoma is a rare malignant bone tumor affecting children and adolescents. PTEN down-regulation or function-loss mutation is associated with the aggressive of osteosarcoma. Explicating the regulatory mechanism of PTEN might highlight new targets for improving the survival rate ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.41279
更新日期:2020-02-03 00:00:00
abstract::Background: Among head and neck squamous cell carcinomas (HNSCCs), hypopharyngeal squamous cell carcinoma (HPSCC) has the worst prognosis. Iron metabolism, which plays a crucial role in tumor progression, is mainly regulated by alterations to genes and post-transcriptional processes. The recent discovery of the N6-met...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.51231
更新日期:2020-10-26 00:00:00
abstract::Monocyte derived macrophages (MDMs) infiltrate sites of infection or injury and upregulate cyclooxygenase-2 (COX-2), an enzyme that stimulates prostaglandin-E2 (PgE2). Nanotheranostics combine therapeutic and diagnostic agents into a single nanosystem. In previous studies, we demonstrated that a nanotheranostic strate...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.41309
更新日期:2020-01-01 00:00:00
abstract::Histone deacetylase 3 (HDAC3) plays a pivotal role in the repression of cartilage-specific gene expression in human chondrocytes. The aim of this study was to determine whether microRNA-193b-3p (miR-193b-3p) regulates the expression of HDAC3 during chondrogenesis and chondrocyte metabolism. Methods: miR-193b-3p expres...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.23547
更新日期:2018-04-15 00:00:00
abstract::Background: Circular RNAs (circRNAs) are a new class of non-coding RNAs (ncRNAs) that are derived from exons or introns by special selective shearing. circRNAs have been shown to play critical roles in various human cancers. However, their roles in renal cell carcinoma (RCC) and the underlying mechanisms remain largel...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.47239
更新日期:2020-08-29 00:00:00
abstract::Proper selection and effective delivery of combination drugs targeting multiple pathophysiological pathways key to spinal cord injury (SCI) hold promise to address the thus far scarce clinical therapeutics for improving recovery after SCI. In this study, we aim to develop a clinically feasible way for targeted deliver...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.26717
更新日期:2018-08-07 00:00:00
abstract::Bacteria-based anticancer therapies aim to overcome the limitations of current cancer therapy by actively targeting and efficiently removing cancer. To achieve this goal, new approaches that target and maintain bacterial drugs at sufficient concentrations during the therapeutic window are essential. Here, we examined ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.16135
更新日期:2016-06-20 00:00:00
abstract::Recent advances in near-infrared (NIR) fluorescence imaging enabled real-time intraoperative detection of bone metastases, bone growth, and tissue microcalcification. Pamidronate (PAM) has been widely used for this purpose because of its high binding affinity toward bone and remarkable therapeutic effects. Herein we d...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.11222
更新日期:2015-03-01 00:00:00
abstract::Photodynamic therapy (PDT) is an emerging theranostic modality for various cancers and diseases. The focus of this study was the development of tumor-targeting albumin nanoparticles containing photosensitizers for efficient PDT. To produce tumor-targeting albumin nanoparticles, the hydrophobic photosensitizer, chlorin...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno/v01p0230
更新日期:2011-04-06 00:00:00
abstract::Extracellular vesicles (EVs), or exosomes, are nanovesicles of endocytic origin that carry host and pathogen-derived protein, nucleic acid, and lipid cargos. They are secreted by most cell types and play important roles in normal cell-to-cell communications but can also spread pathogen- and host-derived molecules duri...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.20576
更新日期:2018-04-09 00:00:00
abstract::Granzyme B (GrB) is an essential cytotoxic effector in cancer immunotherapy as it can be a potential biomarker to predict the efficacy of immunotherapies including checkpoint inhibitors. Monitoring the Granzyme B activity in cells would help determine a patient's clinical response to treatment and lead to better treat...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.37728
更新日期:2020-01-01 00:00:00
abstract::Cancer vaccines have encountered their ideal personalized partner along with evidence for great breakthroughs in the identification and synthesis of neoantigens. Individual cancer neoantigen vaccines are capable of eliciting robust T-cell responses and have been demonstrated to achieve striking clinical efficacy due t...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.24387
更新日期:2018-07-30 00:00:00
abstract::Biological cancer therapies, such as oncolytic, or replication-selective viruses have advantages over traditional therapeutics as they can employ multiple different mechanisms to target and destroy cancers (including direct cell lysis, immune activation and vascular collapse). This has led to their rapid recent clinic...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.3724
更新日期:2012-01-01 00:00:00
abstract::Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due to their biological origin and inherent intercellular biomolecule delivery capability. An in-depth knowledge of their in vivo biodistribution is therefore essential. This work aimed to develop a novel, reli...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.27891
更新日期:2019-02-28 00:00:00
abstract::Cell-derived microparticles (MPs) are nano-sized vesicles released by activated cells in the extracellular milieu. They act as vectors of biological activity by carrying membrane-anchored and cytoplasmic constituents of the parental cells. Although detection and characterization of cell-derived MPs may be of high diag...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.13757
更新日期:2016-03-02 00:00:00
abstract::The limited clinical efficacy of monotherapies in the clinic has urged the development of novel combination platforms. Taking advantage of light-triggered photodynamic treatment combined together with the controlled release of nanomedicine, it has been possible to treat cancer without eliciting any adverse effects. Ho...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.27721
更新日期:2018-11-03 00:00:00